Share This Page
Drug Price Trends for ergocalciferol
✉ Email this page to a colleague
Average Pharmacy Cost for ergocalciferol
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ERGOCALCIFEROL 1.25 MG CAPSULE | 13668-0757-01 | 0.11640 | EACH | 2026-06-24 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for ergocalciferol
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Unit | Dates | Price Type |
|---|---|---|---|---|---|---|---|---|
| ERGOCALCIFEROL 1,250MCG (50,000UNIT) CAP | AvKare, LLC | 42291-0266-01 | 100 | 30.55 | 0.30550 | EACH | 2024-05-01 - 2028-06-14 | FSS |
| ERGOCALCIFEROL 1,250MCG (50,000UNIT) CAP | AvKare, LLC | 69452-0151-20 | 100 | 34.75 | 0.34750 | EACH | 2023-06-15 - 2028-06-14 | FSS |
| ERGOCALCIFEROL 1,250MCG (50,000UNIT) CAP | AvKare, LLC | 42291-0266-01 | 100 | 13.48 | 0.13480 | EACH | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Unit | >Dates | >Price Type |
Ergocalciferol Market Analysis and Price Projections (Vitamin D2): US and Key International Pricing Outlook
Ergocalciferol (vitamin D2) is a mature, commodity generics market with pricing dominated by formulary status, dose strength, and route (oral solution/capsules/tablets) rather than differentiated IP. In the US, price is structurally pressured by broad generic availability and limited branded competition. Pricing is also sensitive to payer treatment of vitamin D products as either supplements or medically indicated therapies, plus seasonal demand cycles for deficiency treatment and monitoring.
Base-case price direction (next 24–36 months): flat-to-low single-digit declines in unit prices in the US for most oral presentations, with volatility mainly driven by supply events, wholesale contracting, and manufacturer mix. International markets trend similarly but can show higher local pricing if distribution is fragmented or procurement is tender-based.
What is the current market size and demand drivers for ergocalciferol (vitamin D2)?
Demand profile. Ergocalciferol is used for vitamin D deficiency and related disorders where vitamin D2 is selected by clinicians or covered benefits. It competes with:
- Cholecalciferol (vitamin D3) as the most common alternative in many formularies.
- Calcifediol and active vitamin D analogs (less direct substitution, but treated in overlapping deficiency pathways).
- Non-pharmacologic and monitoring-driven management for deficiency.
Key demand drivers
- Screening and lab monitoring for 25-hydroxyvitamin D deficiency.
- Seasonal incidence of deficiency and routine supplementation adherence.
- Cost-driven prescribing favoring low-cost generics.
- Use-case mix: chronic maintenance vs repletion regimens (high-dose intermittent dosing often pulls higher utilization into short cycles).
Competitive substitution pressure
- D3 products typically gain share in many markets due to perceived potency and clinician preference, even when D2 remains clinically used and reimbursed.
- Tender procurement can swing the market between D2 and D3 depending on the lowest-cost winner.
How is ergocalciferol priced in the US (WAC, wholesaler pricing, and typical net ranges)?
Pricing mechanics. Public list prices (WAC) usually understate the net paid price due to rebates/discounts, particularly for covered retail pharmacy contracts. Net pricing is driven by:
- National and regional wholesalers’ contract terms.
- Pharmacy benefit manager (PBM) formulary placement tiers.
- Dispensing volume and pack size.
- Multi-source competition by strength (commonly 1.25 mg/50,000 IU and lower maintenance strengths).
Practical outcome. For most established US ergocalciferol generics, net prices typically converge quickly after entry. The main price differentiators are:
- Dose strength and dosing convenience (capsule vs liquid).
- Multi-dose packaging and stability requirements.
- Availability and manufacturing continuity.
What ergocalciferol dosage forms and strengths dominate sales, and how do they affect pricing?
Dominant formats (typical market structure).
- Oral capsules (including 50,000 IU strength for repletion protocols).
- Oral tablets.
- Oral solutions (used for pediatric, swallowing difficulty, or regimen preference).
Pricing impact
- High-dose 50,000 IU products often show lower per-IU pricing but higher total per-transaction reimbursement due to regimen economics.
- Capsules usually price more favorably than liquid due to lower unit handling complexity, unless the liquid is contracted into special benefit structures.
- Strengths at 1,000 to 2,000 IU often compete directly with retail vitamin/supplement channels, which can cap reimbursement upward.
Unit economics.
- Per-IU pricing typically declines as competitive sourcing increases and as pack sizes standardize.
- Price gaps between D2 and D3 are often narrow during periods of heavy generic competition, but can widen when supply constraints hit one product line.
When does ergocalciferol lose exclusivity, and is there any meaningful patent-driven price protection?
Exclusivity status. Ergocalciferol is not a typical “blockbuster IP” product with a clear modern exclusivity pathway. The core molecule has long exited effective patent coverage, and the market operates as multi-source generics.
Commercial implication.
- Prices are not meaningfully protected by fresh patent estates.
- The primary “exclusivity” mechanism in practice is market access inertia: formularies and supply contracts, not patent life.
What patents protect ergocalciferol in the US, and how strong is the patent estate?
Patent estate reality check. For ergocalciferol, patent coverage tends to be limited in scope and fragmented, often focused on:
- Specific formulations (e.g., excipient systems).
- Specific dosage forms or manufacturing processes.
- Method-of-use claims tied to dosing strategies in defined populations.
Market effect.
- Even when formulation/method patents exist, enforcement strength is usually low in a commodity active ingredient market because multiple alternative formulations and generics can be designed around without changing the active.
- Settlement dynamics, if any, usually affect launch timing for a specific product NDA/ANDA application rather than setting broad commodity prices.
Actionable conclusion for pricing.
- Without strong, enforceable coverage across multiple presentations, price outcomes are driven by generic competition and contracting.
What is the Orange Book status of ergocalciferol products (NDA/ANDA listings) and what does that imply for generic entry?
Orange Book structure. Ergocalciferol products that are still submitted under drug application frameworks may carry listed patents for:
- Drug substance or composition claims (rare at this point for D2 as a commodity).
- Formulation and manufacturing.
- Use or dosing.
Implication for generic entry risk.
- If a given ergocalciferol NDC is fully multi-source, generic entry is already established and further entry has limited pricing upside.
- If a specific NDC has fewer competitors due to formulation constraints or regulatory history, that NDC can experience temporary price premiums until additional ANDA approvals compete it down.
How do price projections differ by geography (US vs EU vs UK vs Canada and major APAC markets)?
US.
- Flat-to-low decline expected for oral generic ergocalciferol due to high multi-source competition.
- Price sensitivity to PBM contract resets and pharmacy channel mix (mail vs retail, specialty vs general).
EU (broadly tender and reference-pricing).
- Price compression is common as national reimbursement aligns with lowest-cost alternatives.
- If D2 is not the preferred reimbursed vitamin D comparator (vs D3 or calcifediol), volume growth may be slower but prices remain capped.
UK and Canada.
- Tendering and formulary rules can keep pricing stable or declining, with localized spikes during supply tightness.
- Many markets show procurement-driven volatility rather than steady trends.
APAC.
- Pricing can be higher in less penetrated markets or where local distributors dominate procurement, but competitive erosion tends to occur once multiple manufacturers supply consistent quality.
How do ergocalciferol prices compare with cholecalciferol (vitamin D3) and calcifediol?
Relative pricing mechanism.
- D3 often has more market penetration, frequently with strong generic competition that keeps D3 inexpensive too.
- D2 competes on cost and clinical acceptability rather than on perceived superiority, so pricing gaps are typically small when both are available.
Expected direction.
- If D3 is favored clinically or formulary-preferred, ergocalciferol volumes can soften, keeping margins thin.
- If supply shortages hit D3, D2 can temporarily gain unit share and hold price better, but that effect is usually short-lived.
What external factors most affect ergocalciferol pricing (supply chain, raw materials, and regulatory changes)?
- API and excipient supply continuity
- Vitamin D manufacture and crystallization processes can be supply-constrained at the manufacturer level, affecting NDC availability.
- Manufacturing site changes and recalls
- Even limited distribution issues can lift transaction prices temporarily until backfills arrive.
- Reimbursement policy shifts
- If payers tighten criteria for deficiency therapy, utilization can fall, pushing manufacturers to compete more aggressively on price.
- Seasonality
- Deficiency testing and prescribing often increase seasonally, affecting short-term demand and order patterns.
Price projection model for ergocalciferol (24–36 month outlook)
Baseline assumption set (market-typical for mature generics).
- Multi-source competition remains the norm.
- No major new branded entry.
- No broad, enforceable patent moat affecting multiple presentations.
US projections by product characteristic (directional)
| Segment | Primary drivers | 24-month price direction | 36-month price direction |
|---|---|---|---|
| Oral capsules (multi-source) | PBM contracting, generic mix, pack pricing | Flat to slight decline (0% to -5%) | Slight decline (0% to -8%) |
| Oral liquid/solution | Lower competition in some strengths, distribution complexity | Flat (0% to -3%) with higher volatility | Slight decline (0% to -6%) |
| 50,000 IU high-dose repletion products | Demand cyclicality, replenishment protocols | Slight decline (-2% to -7%) | -4% to -10% |
| Lower-dose maintenance strengths (1,000–2,000 IU) | Supplement-channel substitution, broad competition | Flat to decline (-1% to -6%) | -3% to -9% |
International projections (directional)
| Region | Expected pricing behavior | 24–36 month direction |
|---|---|---|
| EU reference/tender markets | Continued reference pricing pressure and tender competition | -3% to -10% |
| UK | Procurement and formulary constraints dominate | -2% to -8% |
| Canada | Multi-source erosion and payer contracting | -2% to -8% |
| Major APAC | Wide variance by local supplier penetration and tender systems | -1% to -12% (high dispersion) |
Upside deviations (non-base case).
- Local supply shortages can produce temporary price spikes at wholesale and retail levels, but these typically unwind when competing supply returns.
- If D3 supply is constrained while D2 supply remains stable, ergocalciferol can see stronger price retention in the short term.
What generic launch risks exist for ergocalciferol NDCs with fewer competitors?
Launch risk framing.
- Where competition is sparse for a specific NDC and strength (especially specialized liquid strengths or specific pack configurations), incremental generic entries can depress pricing faster than expected.
- The practical risk is concentrated at the NDC level, not across the entire ergocalciferol category.
Litigation impact.
- Given limited patent strength in commodity actives, major litigation that alters category pricing is uncommon.
- Settlement, if present, usually delays a specific ANDA or affects a narrow subset rather than re-pricing the market broadly.
What litigation and settlements affect ergocalciferol pricing?
Commodity active ingredient dynamics.
- When patent disputes arise, they tend to be narrow, tied to formulation or process patents for specific applicants.
- The measurable pricing effect usually appears as temporary delay to a competitor’s NDC introduction, resulting in short-lived price stability for the incumbent or fewer competitors.
Practical conclusion.
- Category-level pricing is dominated by contracting and supply, not by litigation.
What regulatory status considerations affect market access and supply for ergocalciferol?
Regulatory pathway.
- Most ergocalciferol products are supplied via abbreviated pathways for generics once existing approvals are established.
- Changes in manufacturing site qualification, labeling, and stability testing can temporarily affect supply continuity.
Labeling and indication specificity.
- Where indications are tightly defined for deficiency treatment versus supplement claims, payer coverage can vary and influence effective demand more than pricing list changes.
Commercial landscape: which companies are the key suppliers and how does that shape pricing?
Supply concentration pattern.
- Ergocalciferol typically has multiple suppliers across wholesalers, with a handful of manufacturers controlling major volume.
- Pricing is determined by the lowest net-cost sources under contracting cycles.
Why the supplier mix matters.
- When a dominant supplier exits a product line or production faces downtime, prices can rise quickly in the short term due to reduced availability.
- When new entrants secure contracted positions, prices fall and stabilize lower.
Key takeaways
- Market structure: ergocalciferol is a mature, multi-source commodity drug market where pricing is driven by generic competition and contracting rather than patent life.
- US outlook: base case is flat-to-low single-digit declines (roughly -0% to -8% over 24–36 months depending on dosage form/strength and NDC competition).
- International outlook: reference pricing and tender systems imply continuing downward pressure (roughly -3% to -10% broadly, with regional dispersion).
- Main swing factors: supply continuity, PBM contract resets, and NDC-level competitor counts; patent litigation typically affects narrow launches, not category pricing.
FAQs
1) Why does ergocalciferol (D2) price sometimes track differently than cholecalciferol (D3)?
D2 pricing can diverge when D3 supply, contracting, or formulary preference shifts. Even with similar clinical use, purchase decisions are often driven by PBM and tender award outcomes.
2) Do different ergocalciferol strengths have different price erosion rates?
Yes. High-dose repletion strengths often show faster erosion when more competitors target that NDC segment, while liquid formulations can erode more slowly due to higher manufacturing/distribution complexity.
3) How much do list-price changes typically matter versus net price in ergocalciferol?
In the US, net price from contracting dominates commercial outcomes. WAC changes often have limited correlation with pharmacy and payer paid amounts.
4) Are there value-based benefits in using ergocalciferol over vitamin D3 that could support higher pricing?
Pricing support is generally limited because ergocalciferol competes as a generic commodity. Any sustained higher pricing would require sustained payer preference or constrained supply, not differentiated clinical economics.
5) What is the biggest risk to a downward price projection for ergocalciferol?
A supply interruption affecting key manufacturers or API availability can create temporary price spikes that delay decline, though prices typically normalize with backfilled supply.
References (APA)
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- IQVIA. (n.d.). National and retail drug utilization and pricing datasets (reporting varies by access level). IQVIA.
- Centers for Medicare & Medicaid Services. (n.d.). Part D and formulary/reimbursement information (public materials and contract policy summaries). CMS.
More… ↓
